Amendments to the Claims:

Listing of the claims:

This listing of the claims will replace all prior versions, and listing, of the claims in the application:

1. – 33. (Canceled)

34. (Original) A pharmaceutical composition, said composition comprising:

(i) one or more first antibodies or antigen-binding fragments thereof, wherein one or more of said first antibodies or antigen-binding fragments thereof bind immunospecifically to a RSV antigen; and

(ii) one or more second antibodies or antigen-binding fragments thereof, wherein one or more of said second antibodies or antigen-binding fragments thereof bind immunospecifically to a hMPV antigen.

35. (Currently amended) The pharmaceutical composition of claim 34, wherein the amino acid sequence of the RSV antigen is that of any one of SEQ ID NOs:390 to 398~~, respectively~~.

36. (Previously presented) The pharmaceutical composition of claim 34, wherein the amino acid sequence of the RSV antigen is at least 90% identical to the amino acid sequence of RSV nucleoprotein, RSV phosphoprotein, RSV matrix protein, RSV small hydrophobic protein, RSV RNA-dependent RNA polymerase, RSV F protein, or RSV G protein.

37. (Original) The pharmaceutical composition of claim 34, wherein the RSV antigen is selected from the group consisting of RSV nucleoprotein, RSV phosphoprotein, RSV matrix protein, RSV small hydrophobic protein, RSV RNA-dependent RNA polymerase, RSV F protein, and RSV G protein.

38. (Original) The pharmaceutical composition of claim 34, wherein one or more of said first antibodies or antigen-binding fragments thereof immunospecifically bind to an antigen of Group A or Group B RSV.

39. (Original) The pharmaceutical composition of claim 34, wherein the RSV antigen is RSV F protein.

40. (Original) The pharmaceutical composition of claim 34, wherein one or more of said second antibodies cross-react with a turkey APV antigen.

41. (Original) The pharmaceutical composition of claim 34, wherein one or more of said second antibodies are (i) human or humanized antibodies and (ii) cross-react with a turkey APV antigen.

42. (Original) The pharmaceutical composition of claim 40, wherein said turkey APV antigen is selected from the group consisting of turkey APV nucleoprotein, turkey APV phosphoprotein, turkey APV matrix protein, turkey APV small hydrophobic protein, turkey APV RNA-dependent RNA polymerase, turkey APV F protein, and turkey APV G protein.

43. (Original) The pharmaceutical composition of claim 40, wherein said turkey APV antigen is an antigen of avian pneumovirus type A, avian pneumovirus type B, or avian pneumovirus type C.

44. (Currently amended) The pharmaceutical composition of claim 40, wherein the amino acid sequence of said turkey APV antigen is that of any one of SEQ ID NOs:424 to 429~~, respectively~~.

45. (Currently amended) The pharmaceutical composition of claim 34, wherein the amino acid sequence of the hMPV antigen is that of any one of SEQ ID NO: 399-406, 420, and ~~or~~ 421~~, respectively~~.

46. (Original) The pharmaceutical composition of claim 34, wherein the hMPV antigen is selected from the group consisting of hMPV nucleoprotein, hMPV phosphoprotein, hMPV matrix protein, hMPV small hydrophobic protein, hMPV RNA-dependent RNA polymerase, hMPV F protein, and hMPV G protein.

47. (Original) The pharmaceutical composition of claim 34, wherein the hMPV antigen is hMPV F protein.

48. (Original) The pharmaceutical composition of claim 34, wherein the first antibody is Palivizumab; AFFF; P12f2 P12f4; P11d4; Ale9; A12a6; A13c4; A17d4; A4B4; 1X-493L1; FR H3-3F4; M3H9; Y10H6; DG; AFFF(1); 6H8; L1-7E5; L2-15B10; A13a11; A1h5; A4B4(1);A4B4-F52S; or A4B4L1FR-S28R.

49. – 84. (Canceled)

85. (Previously presented) The pharmaceutical composition of claim 34 further comprising one or more third antibodies or antigen-binding fragments thereof, wherein one or more of said third antibodies or antigen-binding fragments thereof bind immunospecifically to a PIV antigen.

86. (Currently amended) The pharmaceutical composition of claim 85, wherein the amino acid sequence of the PIV antigen is that of any one of SEQ ID NOs:407 to 419~~, respectively~~.

87. (Previously presented) The pharmaceutical composition of claim 85, wherein the amino acid sequence of the PIV antigen is at least 90% identical to the amino acid sequence of PIV nucleoprotein, PIV phosphoprotein, PIV matrix protein, PIV small hydrophobic protein, PIV RNA-dependent RNA polymerase, PIV F protein, or PIV G protein.

88. (Previously presented) The pharmaceutical composition of claim 85, wherein the amino acid sequence of the PIV antigen is selected from the group consisting of PIV nucleoprotein, PIV phosphoprotein, PIV matrix protein, PIV small hydrophobic protein, PIV RNA-dependent RNA polymerase, PIV F protein, and PIV G protein.

89. (Currently amended) The pharmaceutical composition of claim 85, wherein one or more of said third antibodies or antigen-binding fragments thereof immunospecifically bind to human PIV type 1 antigen, human PIV type 2 antigen, human PIV type 3 antigen, or human PIV type 4 antigen.

90. (Previously presented) The pharmaceutical composition of claim 34, wherein one or more of said first antibodies or antigen-binding fragments thereof neutralize RSV.

91. (Previously presented) The pharmaceutical composition of claim 34, wherein one or more of said second antibodies or antigen-binding fragments thereof neutralize hMPV.

92. (Previously presented) The pharmaceutical composition of claim 85, wherein one or more of said third antibodies or antigen-binding fragments thereof neutralize PIV.

93 -112 (Canceled)

113. (Previously presented) The pharmaceutical composition of claim 34, wherein one or more of said first antibodies or antigen-binding fragments thereof binds to an antigen of RSV of one group and cross-reacts with the analogous antigen of another group of RSV.